Licensed COVID-19 Vaccine

ApprovedVaccine

GSK

Licensed COVID-19 Vaccine is one of 73 biologic programs targeting Chickenpox. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChickenpoxActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

Influenza, Human+covid-19Active, not recruiting

ChickenpoxPhase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

InfluenzaApproved

Active, not recruiting

Influenza, Human+covid-19Phase 1

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Licensed COVID-19 Vaccine

GSK

Approved

2 2

Bnt162b2

BioNTech

Preclinical

29 3

Biaxin

AbbVie

Preclinical

2 4

Singulair

AstraZeneca

Preclinical

1 5

Activella

Eli Lilly

Preclinical

—6

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

3 9

Piperacillin/tazobactam

Pfizer

Preclinical

1 10

Glucocorticoid

AbbVie

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Influenza, Human+covid-19

NCT07464314

Clinical

Trials by Indication[1]

COVID-192 trials

A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

Completed·NNovavax·Phase 3·NCT04583995·15,185 enrolled

A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People

Completed· BioNTech logo

BioNTech·Phase 1/2·NCT06821061·2,650 enrolled

Immunogenicity1 trial

A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age

Completed· GSK logo

GSK·Phase 2·NCT03652610·996 enrolled

Chickenpox1 trial

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed· GSK logo

GSK·Phase 2·NCT05084508·800 enrolled

Vaccine1 trial

Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine

Completed· GSK logo

GSK··NCT00146835·120,794 enrolled

Influenza1 trial

Immune Response Following Seasonal Influenza Vaccination

Completed· Altimmune logo

Altimmune·Phase 4·NCT03163342·20 enrolled

1 more indication

Influenza, Human+COVID-191 trial

A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

Recruiting· GSK logo

GSK·Phase 1·NCT07464314·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Licensed COVID-19 Vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Licensed COVID-19 Vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Licensed COVID-19 Vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: GSK

Licensed COVID-19 Vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

COVID-192 trials

Immunogenicity1 trial

Chickenpox1 trial

Vaccine1 trial

Influenza1 trial

Influenza, Human+COVID-191 trial

References

Drug Info

Quick Facts

Related News